US Patent Issued to IMMUNEONCO BIOPHARMACEUTICALS (SHANGHAI) on Jan. 20 for "Recombinant protein targeting PD-L1 and VEGF and compositions thereof" (Chinese Inventors)

ALEXANDRIA, Va., Jan. 20 -- United States Patent no. 12,528,866, issued on Jan. 20, was assigned to IMMUNEONCO BIOPHARMACEUTICALS (SHANGHAI) INC. (Shanghai).

"Recombinant protein targeting PD-L1 and VEGF and compositions thereof" was invented by Wenzhi Tian (Shanghai) and Song Li (Shanghai).

According to the abstract* released by the U.S. Patent & Trademark Office: "Disclosed is a recombinant protein containing 1) an anti-PD-L1 antibody heavy chain and an anti-PD-L1 antibody light chain, which two are linked by a disulfide bond to bind PD-L1, and 2) an extracellular Ig-like domain of a vascular epithelial growth factor receptor (VEGFR), linked via a linker to the N-terminus or C-terminus of the heavy chain or the light chain, wherein the ...